^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE3 inhibitor

    Related drugs:
    8d
    Efficacy of Intra-Ureteric Aminophylline Installation After Failed Stone Accessibility by Semi-rigid Ureteroscopy. Prospective Trial (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Al-Azhar University
    New trial
    13d
    RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (clinicaltrials.gov)
    P2/3, N=1000, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)
    23d
    The Role of Levosimendan As Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity (clinicaltrials.gov)
    P3, N=50, Not yet recruiting, Ain Shams University | Initiation date: Jun 2024 --> Dec 2024
    Trial initiation date
    |
    ondansetron
    29d
    MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia (clinicaltrials.gov)
    P2, N=40, Recruiting, MediciNova | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    1m
    Clinical analysis of Levosimendan associated arrhythmia in Heart Failure patients (ChiCTR2400091067)
    P=N/A, N=300, Not yet recruiting, Beijing Shijitan Hospital, Capital Medical University, Beijing; Beijing Shijitan Hospital, Capital Medical University
    New trial
    1m
    Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with cute minor ischemic stroke with CYP2C19 gene function deficiency: A multicenter, open label, and efficacy randomized controlled study (ChiCTR2400091121)
    P4, N=1050, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New P4 trial
    |
    aspirin
    1m
    Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD) (clinicaltrials.gov)
    P1, N=12, Completed, Stalicla SA | Phase classification: P1b --> P1
    Phase classification
    2ms
    RPL554-CO-303: Effect of Ensifentrine Treatment on CAT Score (clinicaltrials.gov)
    P3, N=20, Active, not recruiting, Verona Pharma plc | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    The efficacy of levosimendan and dobutamine on reducing peripheral blood interleukin-6 levels and improving cardiac function in patients with septic cardiomyopathy: a comparative study. (PubMed, J Physiol Pharmacol)
    Additionally, the cTnI level in the levosimendan group was significantly lower than that in the dobutamine group (1.01±0.54 ng/ml vs. 1.40±0.63 ng/ml, P=0.042), and LVEF was significantly higher in the levosimendan group (50.60±6.11% vs. 46.90±4.95%, P=0.042). These findings suggest that levosimendan may reduce plasma IL-6 levels, alleviate myocardial injury, and improve myocardial contractility in patients with septic cardiomyopathy compared to dobutamine.
    Clinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    3ms
    Cilostazol Combats Lipopolysaccharide-Induced Hippocampal Injury in Rats: Role of AKT/GSK3β/CREB Curbing Neuroinflammation. (PubMed, Adv Pharmacol Pharm Sci)
    The findings advocate that cilostazol exerts neuroprotective effects against LPS-induced hippocampal injury by modulating the AKT/GSK3β/CREB pathway and curbing neuroinflammation. Cilostazol may hold promise as a therapeutic agent for neuroinflammatory conditions associated with neurodegenerative diseases.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • GSK3B (Glycogen Synthase Kinase 3 Beta)
    3ms
    Weanilevo: Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS (clinicaltrials.gov)
    P3, N=82, Terminated, Centre Hospitalier Universitaire Dijon | N=210 --> 82 | Trial completion date: Feb 2024 --> Oct 2023 | Recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Oct 2023; There was insufficient funding to continue the study in good conditions.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    3ms
    Cilostazol in Parkinson's Disease (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Ain Shams University
    New P2 trial
    3ms
    TQC3721-II-03: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=240, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=870, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis (clinicaltrials.gov)
    P2, N=180, Recruiting, Verona Pharma plc | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    Cilostazol dexborneol versus placebo for microcirculation dysfunction after reperfusion therapy in patients with acute ischemic stroke with large vessel occlusion (CRYSTAL): A phase IIa, Prospective, multicenter, randomized, double-blind, placebo-controlled parallel trial (ChiCTR2400087944)
    P2, N=60, Completed, Beijing Tiantan Hospital Affiliated to Capital Medical University; NeuroDawn Pharmaceutical Co., Ltd.
    New P2 trial
    |
    MMP9 (Matrix metallopeptidase 9) • CD40LG (CD40 ligand) • S100B (S100 Calcium Binding Protein B)
    3ms
    Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=870, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    3ms
    Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University
    New P3 trial
    |
    aspirin
    4ms
    LevoHeartShock: Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock (clinicaltrials.gov)
    P3, N=610, Recruiting, Central Hospital, Nancy, France | Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Jan 2028 | Trial primary completion date: Jul 2023 --> Feb 2027
    Enrollment open • Trial completion date • Trial primary completion date
    4ms
    Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke (clinicaltrials.gov)
    P3, N=580, Completed, Kafrelsheikh University | Recruiting --> Completed | Trial completion date: Jan 2025 --> Aug 2024 | Initiation date: Feb 2024 --> Jan 2023 | Trial primary completion date: Jan 2025 --> Jul 2024
    Trial completion • Trial completion date • Trial initiation date • Trial primary completion date
    4ms
    Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University | Trial completion date: Mar 2024 --> Dec 2024 | Initiation date: Dec 2021 --> Dec 2023 | Trial primary completion date: Jan 2024 --> Dec 2024
    Trial completion date • Trial initiation date • Trial primary completion date
    4ms
    Clopidogrel Versus Cilostazol in Ischemic Stroke (clinicaltrials.gov)
    P3, N=900, Completed, Kafrelsheikh University | Trial completion date: Jan 2025 --> Aug 2024 | Initiation date: Feb 2024 --> Jun 2022 | Trial primary completion date: Jan 2025 --> Jul 2024 | Recruiting --> Completed
    Trial completion • Trial completion date • Trial initiation date • Trial primary completion date
    4ms
    MN-166-GBM-1201: Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, MediciNova | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date
    |
    temozolomide • Eyevinal (ibudilast)
    4ms
    Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke (clinicaltrials.gov)
    P3, N=580, Recruiting, Kafrelsheikh University | Trial completion date: Jul 2024 --> Jul 2025 | Initiation date: Dec 2022 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    4ms
    Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS (clinicaltrials.gov)
    P2, N=36, Completed, MediciNova | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2024
    Trial completion • Trial completion date
    |
    Eyevinal (ibudilast)
    4ms
    Ticagrelor Versus Cilostazol in Ischemic Stroke (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University
    New P3 trial
    4ms
    A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Verona Pharma plc
    New P2 trial
    4ms
    Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers (clinicaltrials.gov)
    P2, N=70, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel
    4ms
    Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis (clinicaltrials.gov)
    P=N/A, N=106, Not yet recruiting, Chinese Academy of Medical Sciences, Fuwai Hospital
    New trial
    5ms
    The Effect of Cilostazol on Rheumatoid Arthritis Patients (clinicaltrials.gov)
    P2/3, N=70, Active, not recruiting, Ain Shams University | Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    leflunomide
    5ms
    PALMAréa: Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units (clinicaltrials.gov)
    P=N/A, N=27, Completed, Nantes University Hospital | Unknown status --> Completed | N=20 --> 27
    Trial completion • Enrollment change
    5ms
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=120, Recruiting, VA Office of Research and Development | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)
    5ms
    Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds (clinicaltrials.gov)
    P3, N=848, Recruiting, Zhejiang Provincial People's Hospital
    New P3 trial • Head-to-Head
    |
    aspirin
    5ms
    A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    5ms
    Levosimendan Ameliorates Hypoxia-Induced Brain Injury in Rats by Modulating PTEN/Akt Signaling Pathway-Mediated Ferroptosis. (PubMed, Discov Med)
    Levo effectively mitigates brain injury in rats with chronic hypoxia, likely by regulating ferroptosis via the PTEN/Akt signaling pathway.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • IL1B (Interleukin 1, beta)
    5ms
    Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, National Taiwan University Hospital
    New P2 trial
    5ms
    Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Emory University
    New P2 trial
    |
    paclitaxel
    6ms
    The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity (clinicaltrials.gov)
    P3, N=50, Recruiting, Ain Shams University
    New P3 trial
    |
    ondansetron
    6ms
    RPL554-CO-303: Effect of Ensifentrine Treatment on CAT Score (clinicaltrials.gov)
    P3, N=20, Recruiting, Verona Pharma plc | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    RPL554-CO-303: Effect of Ensifentrine Treatment on CAT Score (clinicaltrials.gov)
    P3, N=20, Not yet recruiting, Verona Pharma plc
    New P3 trial
    6ms
    A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. (PubMed, Clin Cancer Res)
    These findings suggest that OPB-171775, with its significant efficacy, could potentially serve as a novel and effective treatment option for advanced GISTs, particularly those resistant to TKIs.
    Journal • Stroma
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDE3A (Phosphodiesterase 3A)